.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The STREAM trial compared a shorter, standardized regimen for rifampicin-resistant tuberculosis with the conventional longer treatment strategy. The randomized phase 3 study showed that a nine-to-eleven-month regimen could achieve favorable outcomes while substantially reducing the duration of treatment compared with the older 20-month approach. The trial is important because treatment duration is closely linked to adherence, toxicity, cost, and the practical burden placed on patients and health systems. For clinicians working in high TB-burden settings, the study illustrates why regimen design cannot be separated from implementation. Shorter therapy can make treatment more feasible, but careful patient selection, drug-resistance testing, toxicity monitoring, and adherence support remain essential. The paper also helps frame the conference discussion on drug-resistant TB: modern care is not only about choosing the right drug combination but also about delivering a regimen that patients can realistically complete. Its relevance extends to programmatic care because the gains from shorter treatment can be lost if diagnosis, follow-up, or access to medicines remains fragmented.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The STREAM trial compared a shorter, standardized regimen for rifampicin-resistant tuberculosis with the conventional longer treatment strategy. The randomized phase 3 study showed that a nine-to-eleven-month regimen could achieve favorable outcomes while substantially reducing the duration of treatment compared with the older 20-month approach. The trial is important because treatment duration is closely linked to adherence, toxicity, cost, and the practical burden placed on patients and health systems. For clinicians working in high TB-burden settings, the study illustrates why regimen design cannot be separated from implementation. Shorter therapy can make treatment more feasible, but careful patient selection, drug-resistance testing, toxicity monitoring, and adherence support remain essential. The paper also helps frame the conference discussion on drug-resistant TB: modern care is not only about choosing the right drug combination but also about delivering a regimen that patients can realistically complete. Its relevance extends to programmatic care because the gains from shorter treatment can be lost if diagnosis, follow-up, or access to medicines remains fragmented.
3 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
